Comparative Pharmacology
Head-to-head clinical analysis: NEO DELTA CORTEF versus NEO MEDROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEO DELTA CORTEF versus NEO MEDROL.
NEO-DELTA-CORTEF vs NEO-MEDROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with potent anti-inflammatory, immunosuppressive, and antiallergic effects. Binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production.
Neo-Medrol is a combination of neomycin (an aminoglycoside antibiotic) and methylprednisolone (a corticosteroid). Neomycin inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, while methylprednisolone suppresses inflammation by binding to glucocorticoid receptors, modulating gene expression, and inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
1-2 drops into the conjunctival sac every 1-2 hours during the day and every 2 hours at night initially, then reduce frequency as inflammation subsides.
Initial dose: 4-48 mg orally per day, divided into 1-4 doses, depending on severity. Intravenous or intramuscular: 10-500 mg/day as methylprednisolone sodium succinate, given as single or divided doses. Intra-articular or soft tissue injection: 4-80 mg as methylprednisolone acetate, depending on joint size.
None Documented
None Documented
Prednisolone: 2-4 hours; clinical context: adrenal suppression lasts 24-36 hours, requiring tapering
Plasma terminal half-life: 2-4 hours (methylprednisolone); clinical effect half-life ~18-36 hours due to receptor occupancy.
Renal: 70-80% as metabolites; biliary: 10-15%; fecal: <5%
Renal (primarily as inactive metabolites); <5% unchanged. Biliary/fecal excretion minimal.
Category C
Category C
Corticosteroid with Antibiotic
Corticosteroid with Antibiotic